IL-15 增强间皮素和 CD70 CAR NK 细胞在 PDAC 中的效力，双靶向未带来额外获益

IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting.

急性髓系白血病双特异性抗体：从骨髓免疫龛到临床转化

Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation.

用于透明细胞肾细胞癌的嵌合抗原受体免疫细胞疗法：最新进展与方向

Chimeric Antigen Receptor-Immune Cell-Based Therapies for Clear Cell Renal Cell Carcinoma: Latest Advancements and Directions.

嵌合抗原受体自然杀伤（CAR-NK）细胞治疗乳腺癌的疗效与安全性评价：系统综述与荟萃分析

Evaluation of Efficacy and Safety of Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cells in Breast Cancer: A Systematic Review and Meta-Analysis.

面向血液肿瘤与实体瘤免疫治疗的高效、无自相残杀的非病毒工程化 CD70 靶向 CAR NK 细胞

Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy.

CAR-T 与 CAR NK 细胞治疗急性髓系白血病的最新进展

Recent advances in CAR T and CAR NK cell therapy for AML.

将去甲基化药物与现货型 CD70 靶向嵌合抗原受体工程化自然杀伤 T 细胞协同用于治疗急性髓系白血病

Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of a

没有 BCMA？没问题：靶向 CD70 的 CAR-NK 细胞在高危骨髓瘤中展现前景

No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma.

靶向 CD70 的 CAR-NK 细胞克服 BCMA 下调并改善高危多发性骨髓瘤模型中的生存

CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models.

DRP1 缺失保护 NK 细胞免受缺氧诱导的功能障碍

DRP1 depletion protects NK cells from hypoxia-induced dysfunction.

这些发现表明，DRP1 失活可在缺氧条件下支持 NK 细胞功能，而代谢工程可能增强 CAR-NK 在实体瘤中的疗效。